Katie Kelley, MD, a gastrointestinal oncologist at UC San Francisco, has received the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). This highly competitive category was open to members at certified cancer centers only. The award, a $100,000 supplement to the Cancer Center Support Grant over a two-year period, will support Kelley’s effort related to her clinical leadership roles.
Katie Kelley, MD
Her clinical research focus lies in the design and conduct of clinical trials of novel targeted agents and combination therapies in hepatocellular carcinoma (HCC) and cancers of the biliary tract.
Her translational research efforts have already enriched the research environment within UCSF. Specifically, Kelley has taken the lead role in addressing the critical need to better understand the complex tumor biology and identify therapeutic targets in hepatobiliary cancers at UCSF.
Kelley began her training and experience in clinical research during the research phase of her fellowship in hematology/oncology at UCSF in 2007 when she joined the Gastrointestinal Oncology Group. As a fellow, Kelley completed the UCSF Clinical and Translational Science Institute (CTSI) course, "Training in Clinical Research" in 2008 and received extensive informal training from mentors in GI Oncology, including Alan Venook, MD; Margaret Tempero, MD; Emily Bergsland, MD; and Andrew Ko, MD.
Focuses on clinical trials of novel targeted agents and
combination therapies in hepatocellular carcinoma
(pictured here) and cancers of the biliary tract.
With support from this award, Kelley will continue her leadership roles and participation in institutional and multi-site trials at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) and will apply her training, education, and leadership skills to the leadership of the Clinical Research Support Office as its director.
Kelley's long-term goal is to build upon her training and experience in translational clinical research, multidisciplinary collaborations, and experience as an Executive Officer for a National Clinical Trial Network to build a Program in Hepatobiliary Cancers at UCSF as well as to contribute substantively to the design and conduct of clinical research across the HDFCCC. Former HDFCCC recipients include Andrew Ko, MD, who received the award in 2012.